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METHODS:
We performed a retrospective review of a prospectively maintained database on prepectoral implantbased breast reconstructions, between January 1, 2017 -October 30, 2018. All patients who were at least 30 days postoperative after tissue expander placement (stage 1) reconstruction were eligible for inclusion in the study.
RESULTS:
There were 169 patients who underwent stage 1 breast reconstruction with prepectoral tissue expander placement. Overall, 135 patients (average age 51.1 years) were included in the study. Postoperative follow-up ranged from 1.2 months (36 days) to 20.5 months (628 days) with a median of 5 months (153 days).
The average BMI was 27.3 kg/m 2 with 37 patients (27.4%) classified as obese. The prevalence of diabetes and tobacco history were each 5%. There were 28 patients (20.7%) who received neoadjuvant chemotherapy and 9 patients (6.7%) with prior breast irradiation. Nipple sparing mastectomies were performed in 73 patients (54%) and 108 patients (80%) underwent bilateral reconstruction. Immediate tissue expander insertion after mastectomy was performed in 111 patients (82%). Complete anterior coverage of the tissue expander with acellular dermal matrix (ADM) was performed in 86% of the immediate reconstruction cases and ADM was used in 25% of the delayed reconstruction cases. There were 33 patients (24%) who received postoperative oral antibiotics for greater than 24 hours following the procedure. The overall rate of complications following stage 1 reconstruction was 23%, with 6 patients experiencing multiple complications. Surgical site infection (23 patients, 17%) and flap and/or nipple necrosis (14 patients, 10%) were the most common complications. There was 1 complication of incision dehiscence. Multivariate analysis demonstrated that both obesity and immediate reconstruction were associated with increased risk of surgical site infection (OR 4.7, p= 0.006 and OR 12.4, p=0.028) , though neither were associated with flap necrosis.
CONCLUSIONS:
The rates of prepectoral breast reconstruction have increased in the past 5 yrs. Limited data exists in the literature describing the safety and rates of complications for this procedure in a large population. This review of a single surgeon's experience with prepectoral breast reconstruction provides additional support for the continued adoption of this technique, given appropriate patient selection and counseling.
Breast Skin Reinnervation following Mastectomy

Amelia Van Handel, Thomas Tung
Washington University, Saint Louis, MO, USA PURPOSE: Skin-sparing mastectomy is a morbid and disfiguring procedure. Breast reconstruction contributes to the patient's recovery both physically and psychologically. However, the spared native breast skin remains insensate which can be annoying and bothersome at the least, and can cause paresthesias and chronic pain at its worse. Over time, some sensitivity may slowly return but it remains crude and very abnormal. The use of innervated flaps for reconstruction can help to restore some sensation but the flap skin paddle is often a small portion of the reconstructed breast surface, the majority of which is made up by denervated native breast skin. Reinnervation of the native breast skin has not been previously described. Our objective is to report a small series of patients who have undergone reinnervation of their native breast skin at the time of mastectomy.
METHODS:
After the mastectomy was completed, and at the time of tissue expander placement, the native breast skin was reinnervated by intercostal sensory nerves. Our first patient underwent direct nerve repair as we were able to identify distal sensory nerves on the mastectomy skin flaps and severed proximal sensory nerves. However we have not been able to consistently identify the distal sensory nerves on the breast skin in subsequent patients and we therefore developed an alternative technique of harvesting intercostal sensory nerves for transfer. These were then coapted directly to the dermis of the underside of the mastectomy skin flaps for sprouting. Usually 2 intercostal nerves were used per side. This technique also provides extra nerve length to help accommodate tissue expansion. Tissue expander placement proceeded in a standard manner and the nerve transfer coaptations were completed with fibrin glue just prior to skin closure to prevent disruption of the nerve transfers during expander placement. The transferred intercostal sensory nerves were also positioned to avoid disruption at the time of second stage implant exchange. Sensation was evaluated postoperatively by Semmes-Weinstein filaments, 2-point discrimination, and patients completed a breast pain questionnaire.
RESULTS:
Five patients have undergone breast skin reinnervation at the time of mastectomy and tissue expander placement, and were compared to an equivalent number of patients who underwent the same procedure without breast skin reinnervation. Follow-up ranged from 6-18 months. Patients who received nerve transfer reinnervation had better return of sensation as measured by both SemmesWeinstein filaments and 2-point discrimination. Data from patient-completed surveys is still under analysis.
CONCLUSION:
Reinnervation of native breast skin following mastectomy is possible and provides better return of sensation. This may help to provide superior and more complete reconstruction by restoring sensation as well as form. The incidence of chronic paresthesias, discomfort or pain may also be reduced and may contribute to a better quality of life in the long term for breast cancer survivors.
Prognostic Factors In Determining The Recurrence Of Desmoplastic Melanoma
Sarah Persing, MD, Raysa Cabrejo, BA, Anjela Galan, MD, Stephan Ariyan, MD, James Clune, MD Yale School of Medicine, New Haven, CT, USA PURPOSE: Desmoplastic melanoma is a rare subclass of melanoma with unique clinical implications. Recent advances in immunotherapy have been shown to be highly effective in the treatment of this type of melanoma. Currently, patients with positive sentinel node biopsies may be candidates for adjuvant immunotherapy without a completion lymphadenectomy. Staging in melanoma relies heavily on sentinel lymph node biopsies. The rate of positive sentinel nodes in desmoplastic melanoma is lower than other sybtypes yet rates of visceral recurrence are similar and rates of local recurrenc are actually higher. Therefore, staging desmoplastic melanoma and predicting those that may benefit from upfront check point inhibitor therapy is difficult. The purpose of this study is to identify patients that are likely to have recurrence utilizing pathological characteristics, mutation analysis and sentinel lymph node biopsies and clinical/demographic characteristics.
METHODS:
From 1998 to 2017, 109 patients with desmoplastic melanoma underwent treatment in the Yale Melanoma Unit. Of these, 71 patients had sentinel lymph node biopsies. All dermatopathology reports, sentinel lymph node biopsy results, demographics, and clinical outcomes were recorded for all patients. A binomial logistic regression was performed with the coefficients of depth of the initial pathology, age, and the number of positive nodes from the sentinel lymph node biopsy. All statistics were done utilizing SPSS 24.
RESULTS:
Desmoplastic melanoma had a recurrence rate of 25% in our cohort. The average age of diagnosis was 69.6 (±13.3) years. The average depth of the desmoplastic melanoma was 4.1 (±3.8) mm. Only 13% of the patients had a positive sentinel lymph node biopsy; 78% of them had complete lymphadenectomies subsequently. Of the patients that had complete lymphadenectomy after a positive sentinel lymph node biopsy, 83% had a recurrence: 40% were intransit and 60% were distant metastasis. The binomial logistic regression calculated an odds ratio of recurrence for depth of 1.03 (p=0.28, CI: 0.82-1.29), for age of 1.07 (p=0.03, CI: 1.01-1.14) and for a positive lymph node of 20.76 (p=0.01, CI: 2.52-171.34).
CONCLUSION:
In this study, we study pathological characteristics, sentinel lymph node biopsies, and overall clinical outcomes. We found that histological characteristics were not a factor in recurrence. A positive sentinel lymph node biopsy and age were statistically significant factors in determining recurrence. Therefore, it is probably beneficial to provide patients with positive sentinel lymph node biopsies upfront check point inhibitor therapy as a preventative treatment for recurrence. However, we believe that there continues to be a subset of patients that have negative sentinel nodes or no sentinel node biopsy that would benefit for adjuvant immunotherapy. We are currently sequencing the desmoplastic tumors from this study to evaluate for mutations that may predict recurrence better than a sentinel node biopsy.
